Morepen Laboratories Ltd

- There was a QIP (Qualified Institutional Placement) fundraising in August prior to February 2025, which raised funds for CAPEX and working capital commitments. - The company is expanding capacity, especially in API manufacturing, with projects like P8 and P9 plants progressing, funded partly through the QIP proceeds. - No explicit mention of any upcoming or planned new fundraising through debt or equity was made during the February 6, 2025 call. - The promoter's participation in a new subsidiary involves capital contribution, but specifics on amount or fundraising plans there were not detailed. - The company appears focused on internal funding from these sources and operational cash flow for growth, with no declared immediate plans for fresh external financing.

- Morepen Laboratories is expanding API capacities with a total planned capacity of 600 KL, of which 510 KL is already completed and ready for production. The remaining capacity will be completed within 6 to 9 months. - The P8 plant has been inaugurated with installation of 6 big reactors and 2 small reactors, P9 block construction is ongoing, followed by expansion of P10. - New 120,000 sq. ft. facility construction is nearly complete (around 70% finished last update) for production and expansion. - Medical devices capacity is being expanded: BP monitor capacity increased in existing facilities, glucose monitor capacity also being expanded. - The new building will house around 20 additional injection molding machines, speeding up manufacturing. - The company is focusing on growing export markets and has participated in international exhibitions such as MEDICA (Germany) and Arab Health (Dubai). - Promoters are required to contribute capital equally in a newly incorporated medical device subsidiary, supporting asset acquisition and growth. These investments reflect a strategic focus on increasing API production, expanding medical device manufacturing, and scaling exports.

- FY25 revenue target is around Rs. 1,900 crore with 10%-11% growth, not official guidance but expected. - Pharma business expected to grow modestly; API business growth expected between 10%-15% based on market conditions. - Formulation and OTC business projected to grow around 25% in FY26 with overall EBITDA margins of 11%-12%. - Medical devices grew 15% in Q3 compared to last year; expected CAGR of about 20% over the long term. - Glucometer base expanding; 13.5 million meters installed driving strip sales. - Capacity expansions (API capacity increasing from 510 KL to 600 KL) to support growth over next 6-9 months. - Expected market corrections with some quarters slow; long-term view remains positive. - Export business strong, maintaining 70:30 export-to-domestic ratio, aiding growth. - China price stabilization expected to improve demand and growth.

- Morepen expects modest revenue growth of 10%-15% in the near term, with a long-term CAGR target of around 17%-18% depending on market conditions (Page 16, 27). - For FY25, a target of around Rs. 1,900 crore revenue is anticipated, reflecting approximately 10%-11% growth (Page 26). - EBITDA margin expected between 11%-12% as formulation and OTC businesses grow (Page 17). - Profit after tax (PAT) for nine months already Rs. 98 crore, surpassing last full year, with full-year EPS target around Rs. 2.5 (Page 4, 15). - Long-term CAGR of 20% growth over FY26-FY27 across all business segments is maintained but initial years may show slower growth (Page 19). - Growth driven by new product launches, patent expiries (e.g., empagliflozin, sitagliptin), and expansion in finished dosage formulations, which offer higher margins (Page 16-17). - Medical devices expected to grow steadily, with 15% growth in recent quarters and capacity expansions underway (Page 23).

- Regarding the current and expected order book, Sushil Suri mentions that in the last quarter (Q4), the API segment usually receives good orders from international customers as they place new orders in January and February after year-end closing. - However, he notes it is too early to comment specifically on the current quarter's order book or provide guidance. - Prices are stabilizing, which is positive for new order formation, but demand needs time to pick up after a typically quiet March quarter due to trade business inventory reductions and tax/GST payments. - Overall, the company maintains a firm focus on demand and product requirement rather than just margin fluctuations. - No exact figures or definite order book numbers are given in the discussion on page 27.